American Gene Technology
Company/ Institution Name: American Gene Technologies
Company Category: Infectious Disease, Metabolic Disease, Oncology
Company Website: https://www.americangene.com/
Company Description: AGT is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. AGT's mission is to transform people's lives through genetic medicines that rid the body of disease. AGT has received 3 patents for the technology used to make the AGT103-T cell product and ten patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2022.
Leading Pipeline: Phase I
IP Status: China, Other Regions
Company Headquarter: United States of America
Partnering Objectives: Fund Raising, Licensing
Project Introduction:
AGT is a clinical gene and cell therapy company with a proprietary gene-delivery platform for the rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. AGT enrolled the first participant in our HIV cure trial (AGT103-T ) in November. Safety data is expected in April, and we hope to see efficacy data in the Summer of 2021. Assuming positive results, we may begin the IPO process in the Fall.
AGT's mission is to transform people's lives through genetic medicines that rid the body of disease. AGT has received 3 patents for the technology used to make the AGT103-T cell product and ten patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2022.
Company Presentation:
